MYBL2 and non-small cell lung carcinoma: Among them, CENPA (Mullen et al., 2020), DNMT1 (Wu et al., 2020), MYBL2 (Mullen et al., 2020), TFDP1 (Zhan et al., 2017), ZNF367 (Liu Z. et al., 2018), HMGA1 (Zhang Z. et al., 2015), HMGA2 (Gao et al., 2018), and FOXM1 (Mullen et al., 2020) were previously shown to be highly associated with NSCLC progression.